News & Events

Abbott recently hosted a webinar exploring the clinical role of kappa and lambda free light chain testing in the diagnosis and monitoring of plasma cell disorders such as multiple myeloma. Key points include the use of the kappa/lambda ratio to identify abnormal monoclonal protein production and how free light chain assays complement serum protein electrophoresis and immunofixation to support more …

SAN DIEGO, CA - January 14, 2026 - Diazyme Laboratories, Inc. announces receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the evaluation of monoclonal gammopathy of undetermined significance (MGUS) for Diazyme’s Kappa and Lambda Free Light Chain Assays. “FDA 510(k) clearance of added indication to our free light chain kappa and lambda assays demonstra …

Improving Oncology Diagnostics with Diazyme’s Free Light Chain Assays In the fight against multiple myeloma and related plasma cell disorders, speed and accuracy in diagnostics are essential. For New England Cancer Specialists (NECS), one of the region’s leading oncology practices, bringing free light chain testing in-house was a critical step in improving patient care. James DiPhilipp …

At Diazyme Laboratories, we take pride in offering innovative diagnostic solutions that empower healthcare professionals to make informed decisions. One such professional who has played a significant role in advancing diagnostic testing is Dr. Alan H.B. Wu, Ph.D. For nearly a decade, Dr. Wu has been a trusted and loyal customer, helping to shape the future of diagnostics by using Diazyme’s u …